---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-032658"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:48:27.844877+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics raises BRIUMVI revenue guidance to $585M, Q3 net income $390.9M

## Summary
- Q3 2025 total revenue $161.7M, BRIUMVI US net revenue $152.9M up 84% YoY.
- Raises FY2025 BRIUMVI US net revenue target to ~$585M (prior $570-575M) and global target to $600M.
- Q3 net income $390.9M includes $365M non-recurring tax benefit; net income $3.9M in Q3 2024.
- Completed $100M buyback (3.5M shares at avg $28.55); authorized new $100M repurchase program.
- Phase 3 subcutaneous ublituximab enrollment commenced; ENHANCE trial for consolidated IV dosing fully enrolled.

## SEC filing metadata
- accession: 0001437749-25-032658
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774925032658/0001437749-25-032658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774925032658/tgtx20250909_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-032658
- JSON: https://secwatch.observer/filing/0001437749-25-032658.json
- Plain text: https://secwatch.observer/filing/0001437749-25-032658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.